|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01652 FUSEN PHARM
Nominal 
1.260 +0.010 (+0.800%) | 2025/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | |
| Turnover | -- | -- | 326,029 | 565,608 | 491,757 | 385,664 |
| Cost of Sales | -- | -- | (163,392) | (266,102) | (266,736) | (174,531) |
| Gross Profit | -- | -- | 162,637 | 299,506 | 225,021 | 211,133 |
| 2025/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | -- | -- | -- | -- | (38,007) | (19,280) | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | -- | -- | (104,097) | (40,621) | (21,019) | (1,969) | |
| Profit / (Loss) before Taxation | -- | -- | (190,446) | (29,448) | (30,993) | 23,791 | |
| Taxation | -- | -- | 1,646 | (6,847) | (3,661) | (7,178) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | -- | -- | 17 | 18 | 49 | 32 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | (11,784) | -93.758% | (188,783) | (36,277) | (34,605) | 16,645 | |
| 2025/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | |
| Net Finance Costs / (Income) | -- | -- | 18,838 | 8,843 | 15,725 | 7,097 |
| Depreciation & Amortisation | -- | -- | 41,711 | 35,798 | 34,161 | 23,785 |
| Directors' Emoluments | -- | -- | 2,702 | 5,769 | 2,580 | 2,655 |
| 2025/12 - Final | %Chg (Compare to Final) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| Auditor's Opinion Status | N/A | -- | Unqualified (Modified Report) | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2025/12 - Final | %Chg (Compare to Final) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| EPS (cts) | -1.590 | -93.885% | -26.000 | -5.000 | -5.000 | 2.000 |
| DPS (cts) | 0.000 | -- | 0.000 | 0.000 | 0.000 | 0.910 |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | -- | 45.500% |
| Cash flow per share ($) | -- | -- | 0.181 | (0.027) | 0.146 | 0.062 |
| NBV per share ($) | -- | -- | 0.500 | 0.751 | 0.810 | 0.855 |
| Remarks: | Real time quote last updated: 02/04/2026 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB -11,784 |
| %Change | -93.758% |
| EPS / (LPS) | RMB -0.016 |
| NBV Per Share (¥) | RMB -- |